93 related articles for article (PubMed ID: 28394971)
41. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
Schrijnders D; Houweling ST; Landman GW
Diabetes Care; 2015 Jun; 38(6):e94. PubMed ID: 25998308
[No Abstract] [Full Text] [Related]
42. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.
Aquilante CL
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):359-72. PubMed ID: 20222815
[TBL] [Abstract][Full Text] [Related]
43. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
Evans JM; Ogston SA; Emslie-Smith A; Morris AD
Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
[TBL] [Abstract][Full Text] [Related]
44. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
45. Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
Sevinc A
Arch Intern Med; 2003 Jul; 163(14):1741. PubMed ID: 12885691
[No Abstract] [Full Text] [Related]
46. Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
Genuth S
Diabetes Care; 2015 Jun; 38(6):e95. PubMed ID: 25998309
[No Abstract] [Full Text] [Related]
47. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Bowker et Al.
Farooki A; Schneider SH
Diabetes Care; 2006 Aug; 29(8):1989-90. PubMed ID: 16873827
[No Abstract] [Full Text] [Related]
48. [Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
Procacci V; Giovine A; Roberto MG; Di Reda N; Lasorsa G; Vendemiale G; Stufano N; Altomare E
Boll Soc Ital Biol Sper; 1988 Sep; 64(9):817-24. PubMed ID: 3072977
[No Abstract] [Full Text] [Related]
49. [Pharmacodynamics of second-generation sulfonylureas: dose-effect curve of gliquidone in type II diabetics].
Procacci V; Giovine A; Roberto MG; Ronchi AM; Lasorsa G; Vendemiale G; Stufano N; Altomare E
Boll Soc Ital Biol Sper; 1988 Aug; 64(8):731-8. PubMed ID: 3214573
[No Abstract] [Full Text] [Related]
50. Combination use of sulfonylureas and insulin in the treatment of noninsulin-dependent diabetes mellitus.
Montgomery PA
Pharmacotherapy; 1992; 12(4):292-9. PubMed ID: 1518728
[TBL] [Abstract][Full Text] [Related]
51. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
Rustenbeck I
Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
[TBL] [Abstract][Full Text] [Related]
52. Does mortality risk vary among sulfonylureas?
Pantalone KM
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240
[No Abstract] [Full Text] [Related]
53. Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?
Riddle MC
J Clin Endocrinol Metab; 2003 Feb; 88(2):528-30. PubMed ID: 12574174
[No Abstract] [Full Text] [Related]
54. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
55. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke.
Kunte H; Schmidt S; Eliasziw M; del Zoppo GJ; Simard JM; Masuhr F; Weih M; Dirnagl U
Stroke; 2007 Sep; 38(9):2526-30. PubMed ID: 17673715
[TBL] [Abstract][Full Text] [Related]
56. [Sulfonylureas and glinides].
Hirose T
Nihon Rinsho; 2006 Dec; 64 Suppl 9():646-53. PubMed ID: 17458297
[No Abstract] [Full Text] [Related]
57. Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas.
Chatterjee R; Edelman D
J Gen Intern Med; 2016 Jun; 31(6):650. PubMed ID: 26992707
[No Abstract] [Full Text] [Related]
58. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke.
Arboix A
Stroke; 2007 Sep; 38(9):2413-4. PubMed ID: 17673799
[No Abstract] [Full Text] [Related]
59. [Reply. Inappropriate use of sulfonylureas in older adults].
Passi Á
Rev Med Chil; 2016 Nov; 144(11):1497-1498. PubMed ID: 28394971
[No Abstract] [Full Text] [Related]
60. [Inappropriate use of sulfonylureas in older adults].
Pacheco J
Rev Med Chil; 2016 Nov; 144(11):1497. PubMed ID: 28394970
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
